Enlicitide clinical trials
Also written MK-0616.
Includes 15 studies of MK-0616 and 4 studies of Enlicitide chloride.
How each study uses enlicitide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enlicitide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Jul 2026 · LIPFENDRA · NDA 220848 (FDA, Drugs@FDA; as MK-0616)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2024 (10)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 33 · Other 0
Often tested with
Tested in the same studies.
Rosuvastatin (2) · MK-7262 (2) · Alendronate (1) · Lithium Carbonate (1) · Atorvastatin (1) · Thyroxine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test enlicitide, phase 3 first.
- Nov 2027A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)Phase 3 · Merck Sharp & Dohme LLC
- Dec 2026A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Phase 1 · Merck Sharp & Dohme LLC
- Oct 2027A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)Phase 2 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses enlicitide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07058077Written as Enlicitide Decanoate
- A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07614984Written as Enlicitide
- A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07821944Written as Enlicitide Decanoate
- A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)CompletedPhase 1Merck Sharp & Dohme LLCNCT07300280Written as Enlicitide
- A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)CompletedPhase 1Merck Sharp & Dohme LLCNCT06643377Written as Enlicitide
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT05934292Written as Enlicitide Decanoate
- A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT07619443Written as Enlicitide
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedPhase 3Merck Sharp & Dohme LLCNCT05952856Written as Enlicitide Decanoate
- A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Active, not recruitingPhase 1Merck Sharp & Dohme LLCNCT07776665Written as Enlicitide
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT07216482Written as Enlicitide
- A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)CompletedPhase 1Merck Sharp & Dohme LLCNCT05070390Written as Enlicitide Chloride
- A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)CompletedPhase 1Merck Sharp & Dohme LLCNCT07481708Written as Enlicitide
- A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)CompletedPhase 1Merck Sharp & Dohme LLCNCT06575959Written as Enlicitide
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef OutcomesActive, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06008756Written as Enlicitide Decanoate
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)CompletedPhase 3Merck Sharp & Dohme LLCNCT06450366Written as Enlicitide
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedPhase 3Merck Sharp & Dohme LLCNCT05952869Written as Enlicitide Decanoate
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionActive, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06492291Written as Enlicitide Decanoate
- A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)CompletedPhase 1Merck Sharp & Dohme LLCNCT07044479Written as Enlicitide
- A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)CompletedPhase 1Merck Sharp & Dohme LLCNCT06880874Written as Enlicitide
- A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)CompletedPhase 1Merck Sharp & Dohme LLCNCT06772792Written as Enlicitide Decanoate
See all 33 studies that test enlicitide →
Given beside what is tested · 1 — enlicitide is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Results posted1
- A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)Oct 20, 2026NCT06643377
Codes
What other systems call enlicitide · ClinicalTrials.gg INT017768
- UNII (FDA) R7EZ772VG2ENLICITIDEOne source FDA
- NCI Thesaurus C223713EnlicitideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R7EZ772VG2 | ENLICITIDE | One source FDA |
| NCI Thesaurus | C223713 | Enlicitide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.